Efimosfermin Alfa
AssetAlso called Efimosfermin, BOS-580, LLF-580
Long-acting FGF21 analog activates FGFR–beta-Klotho signaling to improve lipid metabolism and insulin sensitivity.
- Stage
- Phase 3
- Modality
- Protein or enzyme
- Target
- FGFR1
- 4
- Indications
- 10
- Trials
- 2
- Developers
Indications
4Metabolic dysfunction-associated steatohepatitis
Phase 3, Recruiting, NCT07701993, clinicaltrials.gov, Oct 31, 2026
Metabolic dysfunction-associated steatotic liver disease
Phase 3, Recruiting, NCT07221188, clinicaltrials.gov, Oct 31, 2026
NASH with fibrosis
Phase 3, Not yet recruiting, CTIS2026-525757-37-00, euclinicaltrials.eu, Oct 17, 2026
1 more
In the full profile
- Target and mechanism2
- Owner and partners2
- Trials10
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.